Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic Cancers

키워드

참고문헌 (30)

1. Motzer RJ, "Nivolumab versus everolimus in advan-ced renal-cell carcinoma", N Engl J Med, 373, pp.1803~1813 (2015)
2. Herbst RS, "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010) : a randomised controlled trial", Lancet, 387, pp.1540~1550 (2016)
3. Gibney GT, "Predictive biomarkers for checkpoint inhibitor-based immunotherapy", Lancet Oncol, 17, pp.e542~e551 (2016)
4. Duffy MJ, "Biomarkers for predicting response to immunotherapy with immune checkpoint inhibitors in cancer patients", Clin Chem, 65, pp.1228~1238 (2019)
5. Moreira L, "Identification of Lynch syndrome among patients with colorectal cancer", JAMA, 308, pp.1555~1565 (2012)
6. Le DT, "Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade", Science, 357, pp.409~413 (2017)
7. Marabelle A, "Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability", mismatch repair-deficient cancer : results from the phase II KEYNOTE-158 study, 2020, pp.38, 1~10
8. Le DT, "PD-1 blockade in tumors with mismatch-repair deficiency", N Engl J Med, 372, pp.2509~2520 (2015)
9. Dudley JC, "Microsatellite ins-tability as a biomarker for PD-1 blockade", Clin Cancer Res, 22, pp.813~820 (2016)
10. Cortes-Ciriano I, "A molecular portrait of microsatellite instability across multiple cancers", Nat Commun, 8, pp.15180~ (2017)
11. Bonneville R, "Landscape of microsatellite instability across 39 cancer types", JCO Precis Oncol, 2017, pp.PO.17.0007~ (2017)
12. Petrelli F, "Outcomes following immune checkpoint inhibitor treatment of patients with microsatellite instability-high cancers : a systematic review and meta-analysis", JAMA Oncol, 6, pp.1068~1071 (2020)
13. Murphy MA, "This article is a US Government work and, as such, is in the public domain of the United States of America", Int J Cancer, 129, pp.1914~1922 (2011)
14. Lazo PA, "The molecular genetics of cervical carcinoma", Br J Cancer, 80, pp.2008~2018 (1999)
15. da Silva EM, "Mesonephric and mesonephric-like carcinomas of the female genital tract : molecular characterization including cases with mixed histology and matched metastases", Mod Pathol, 34, pp.1570~1587 (2021)
16. Horn LC, "Mesonephric-like adenocarcinomas of the uterine corpus : report of a case series and review of the literature indicating poor prognosis for this subtype of endometrial adenocarcinoma", J Cancer Res Clin Oncol, 146, pp.971~983 (2020)
17. Veras E, "PD-L1 expression in human placentas and gestational trophoblastic diseases", Int J Gynecol Pathol, 36, pp.146~153 (2017)
18. Bolze PA, "PD-L1 expression in premalignant and malignant trophoblasts from gestational trophoblastic diseases is ubiquitous and independent of clinical outcomes", Int J Gynecol Cancer, 27, pp.554~561 (2017)
19. Choi MC, "Effective anti-programmed cell death 1 treatment for chemoresistant gestational trophoblastic neoplasia", Eur J Cancer, 121, pp.94~97 (2019)
20. You B, "Avelumab in patients with gestational trophoblastic tumors with resistance to single-agent chemotherapy : cohort A of the TROPHIMMUN phase II trial", J Clin Oncol, 38, pp.3129~3137 (2020)
21. Schwitalle Y, "Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers", Gastroenterology, 134, pp.988~997 (2008)
22. Santin AD, "Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer(NCT02257528", NRG-GY002), 2020, pp.157, 161~166
23. Matulonis UA, "Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer : results from the phase II KEYNOTE-100 study", Ann Oncol, 30, pp.1080~1087 (2019)
24. Hamanishi J, "Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer", J Clin Oncol, 33, pp.4015~4022 (2015)
25. Ott PA, "Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer : results from the KEYNOTE-028 study", J Clin Oncol, 35, pp.2535~2541 (2017)
26. Hasegawa K, "Efficacy and safety of nivolumab(Nivo)in patients(pts)with advanced or recurrent uterine cervical or corpus cancers", J Clin Oncol, 36(15_Suppl), pp.5594~ (2018)
27. Davis AA, "The role of PD-L1 expression as a predictive biomarker : an analysis of all US Food and Drug Administration(FDA)approvals of immune checkpoint inhibitors", J Immunother Cancer, 7, pp.278~ (2019)
28. Chalmers ZR, "Analysis of 100, 000 human cancer genomes reveals the landscape of tumor mutational burden", Genome Med, 9, pp.34~ (2017)
29. Magee DE, "Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors : a systematic review and meta-analysis of randomized clinical trials", Ann Oncol, 31, pp.50~60 (2020)
30. Makker V, "Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer", J Clin Oncol, 38, pp.2981~2992 (2020)

관련 논문AI추천